OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company focused on antibody discovery technologies, including proprietary transgenic animal platforms and AI-enabled screening capabilities licensed to pharmaceutical and biotech partners on a royalty-based model. The company completed its de-SPAC merger with Avista Public Acquisition Corp. II, sponsored by Avista Capital Holdings, in November 2022 following the blank-check vehicle's 2021 IPO. OmniAb operates in the life sciences tools and services sector and remains publicly listed on Nasdaq. The company filed an 8-K with the SEC on June 18, 2026. For full filing history, sponsor details, and deal analytics on OABI, sign up for complete access at SpacDesk.